These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18062726)

  • 41. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
    Moltó J; Santos JR; Pérez-Alvarez N; Cedeño S; Miranda C; Khoo S; Else L; Llibre JM; Valle M; Clotet B
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3928-32. PubMed ID: 18725446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
    AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.
    Biscione FM; Westin MR; Ribeiro KM; Estevam DL; Cardoso SW; Tenore SB; Neto LF; Alencastro PR; Suffert TA; de Moraes MJ; Barbosa AN; Morejón KM; de Arruda ÉA; Silveira JM; Neto JL; Greco DB; Tupinambás U
    J Int Assoc Provid AIDS Care; 2014; 13(1):63-8. PubMed ID: 24134962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
    McKeage K; Scott LJ
    Paediatr Drugs; 2010 Apr; 12(2):123-31. PubMed ID: 20218748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Darunavir: a second-generation protease inhibitor.
    Busse KH; Penzak SR
    Am J Health Syst Pharm; 2007 Aug; 64(15):1593-602. PubMed ID: 17646561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
    Blanche S; Bologna R; Cahn P; Rugina S; Flynn P; Fortuny C; Vis P; Sekar V; van Baelen B; Dierynck I; Spinosa-Guzman S
    AIDS; 2009 Sep; 23(15):2005-13. PubMed ID: 19724191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Darunavir in treatment-naïve patients. The ARTEMIS study].
    Estrada V; Fuster M
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chemical characteristics, mechanism of action and antiviral activity of darunavir].
    Pasquau Liaño J; Hidalgo Tenorio C
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():3-9. PubMed ID: 19195453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Darunavir: promising initial results.
    MacArthur RD
    Lancet; 2007 Apr; 369(9568):1143-4. PubMed ID: 17416241
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
    Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase III results of second-generation HIV protease inhibitor reported.
    Oncology (Williston Park); 1998 Nov; 12(11):1616. PubMed ID: 9834939
    [No Abstract]   [Full Text] [Related]  

  • 58. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C; Pavie J; Palmer P; Ghosn J; Blanche S; Roudiere L; Dominguez S; Mortier E; Molina JM; de Truchis P
    AIDS; 2008 Sep; 22(14):1809-13. PubMed ID: 18690163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.